Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00123890 |
The purpose of this study is to determine eligibility for one of three treatment studies of the CCR5 antagonist GW873140 or an observational study without GW873140. No investigational treatment will be administered through this study.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: GW873140 |
Phase III |
Study Type: | Interventional |
Study Design: | Diagnostic, Uncontrolled, Safety/Efficacy Study |
Official Title: | A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-Tropic and R5/X4-Tropic HIV-1 Infected, Treatment-Experienced Subjects With Drug-Resistant Virus or an Observational Study. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Study Director: | GSK Clinical Trials, Ph.D. | GlaxoSmithKline |
Study ID Numbers: | CCR104627 |
Study First Received: | July 22, 2005 |
Last Updated: | November 21, 2005 |
ClinicalTrials.gov Identifier: | NCT00123890 |
Health Authority: | United States: Food and Drug Administration; Denmark: Danish Medicines Agency; Belgium: Ministry of Social Affairs, Public Health and the Environment |
HIV-1
GW873140
CCR5 antagonist
experienced |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |